Trial · NCT07098338
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
NCT07098338, Phase 2, Recruiting, AstraZeneca
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC). Trials, record NCT07098338. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07098338
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
- NCT number
- NCT07098338
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 278 participants, estimated
- Lead sponsor
- AstraZeneca
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Rilvegostomig, Ramucirumab, Dato-DXd
- First posted
- 2025-08-01
- Last updated
- 2026-10-15
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of participants with adverse events (AE) and serious adverse events (SAE) | Through study completion, an average of 3 years | To assess the safety and tolerability |
| Primary | Objective response rate (ORR) | Through study completion, an average of 3 years | ORR is defined as the proportion of participants who have a confirmed CR (complete response) or confirmed PR (partial response) per RECIST 1.1 |
| Secondary | Best Overall Response(BOR) | Through study completion, an average of 3 years | BOR is the best response a participant has had following randomisation/start of dosing, but prior to starting any subsequent cancer therapy and up to and including RECIST progression or the last evaluable assessment in the absence of RECIST progression |
| Secondary | Change in Target Lesion Tumor Size | Through study completion, an average of 3 years | The best percentage change from baseline in Target Lesion tumour size is the largest decrease (or smallest increase) from baseline for a participant, using RECIST 1.1 assessments |
| Secondary | Progression free survival (PFS) | Through study completion, an average of 3 years | PFS is defined as the time from the start of treatment until the date of objective disease progression or death (by any cause in the absence of progression) per RECIST 1.1. |
| Secondary | Disease Control Rate(DCR) at 12 Weeks | From Day 1 pre-dose to 12 weeks | DCR at 12 weeks is defined as the percentage of participants who have a best objective response of confirmed CR or PR or who have SD for at least 11 weeks after start of treatment (to allow for an early assessment within the assessment window). |
| Secondary | Duration Of Response (DoR) | Through study completion, an average of 3 years | The DoR is defined as the time from the date of first documented objective response (which is subsequently confirmed) until date of first documented disease progression or death (by any cause in the absence of disease progression). |
| Secondary | Overall Survival(OS) | Through study completion, an average of 3 years | OS is defined as the time from the start of treatment until death due to any cause. |
| Secondary | Serum concentration | Through study completion, an average of 3 years | To assess the serum concentration of the novel anti-cancer agents in combination. |
| Secondary | Maximum plasma drug concentration (Cmax) | Through study completion, an average of 3 years | To assess the Cmax of the novel anti-cancer agents in combination. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07098338
GET https://conductscience.org/api/trials/v1/NCT07098338/registered